Biotech Analyst Watsek and Biopharma & Biotech Analysts Chen and Kim provide a review of ASH 2022 of emerging therapies for Hematologic Malignancies: AML, MDS, MM and CLL on an Analyst/Industry conference call to be held on December 14 at 11 am. Webcast Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on KURA:
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- Kura Oncology presents updated clinical data from KOMET-001 trial
- Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting
- Kura Oncology to Host Investor EventĀ on December 10, 2022
- Kura Oncology to Participate in Two Upcoming Investor Conferences